1. Introduction {#sec1}
===============

Crohn\'s disease is an inflammatory bowel disease that may present with systemic symptoms such as fever, fatigue, and weight loss, as well as abdominal symptoms including pain and diarrhea \[[@B1]\]. Unlike ulcerative colitis, Crohn\'s disease can manifest anywhere in the gastrointestinal tract, though it most commonly affects the terminal ileum and colon. It is estimated that almost 50% of patients with Crohn\'s disease will have involvement of the small bowel, and up to 30% will have small bowel involvement only \[[@B2]\]. Crohn\'s disease is most often diagnosed by a combination of clinical features, endoscopy, and histopathology. Although the exact pathogenesis is still unclear, the disease manifests itself endoscopically as focal ulcerations with skip lesions (normal appearing bowel along with areas of inflammation) \[[@B1]\].

Recently, there has been an increase in the use of imaging modalities in assisting the diagnosis of Crohn\'s disease as well as assessing disease severity. Conventional enteroclysis, ultrasound (US), computed tomography (CT), and magnetic resonance (MR) imaging have all been used to detect inflammation in the bowel \[[@B3], [@B4]\]. The use of imaging for diagnosing small bowel activity has become even more relevant since traditional methods of diagnosis (e.g., endoscopy) are not able to visualize the small bowel reliably, and up to 10% of patients will have small bowel involvement not amenable to visualization by endoscopy \[[@B1]\]. Additionally, endoscopic methods of assessment carry the risk of procedural complications and can cause patient discomfort \[[@B5]\].

Multiple studies have investigated the use of imaging to diagnose small bowel activity in Crohn\'s patients. Although the use of conventional enteroclysis and CT have shown good diagnostic accuracy, they are limited by exposure to ionizing radiation \[[@B6]\]. Ultrasound is a nonradiating form of imaging but is limited because image quality is dependent on technician expertise \[[@B7]\].

Magnetic resonance has become a useful modality for assessing small bowel activity in Crohn\'s disease, with multiple studies showing great sensitivity and specificity. The use of enteral contrast agents using MR enterography protocols has allowed for better distention as well as visualization of the small bowel \[[@B8]\]. Previous studies and reviews have looked at the use of MR in Crohn\'s disease; however these studies were limited in only assessing small bowel activity or extraluminal complications \[[@B9], [@B10]\]. Multiple new studies have since emerged looking at this field. In this study, we performed a systematic review and meta-analysis on the use of MR in detecting small bowel activity as well as intra- and extraluminal complications in Crohn\'s patients. We also determined whether the use of MR enteroclysis, a recent method of administrating contrast, yields any advantages over conventional MR enterography.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We performed a comprehensive search strategy with the use of electronic databases including MEDLINE, EMBASE, CINAHL, and Cochrane Central Register of Controlled Trials. All relevant articles published until October 2, 2014, were included. Our search strategy included individual and combinations of relevant terms including "Crohn\'s", "inflammatory bowel disease", and "magnetic resonance" (see Supplementary Table 1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/7857352> for comprehensive search terms used). References of selected articles and previously published review articles were also manually searched to identify relevant studies.

2.2. Study Selection and Data Extraction {#sec2.2}
----------------------------------------

Our inclusion criterion was any study that compared the use of magnetic resonance to diagnose small bowel activity in Crohn\'s disease. We used as a reference standard surgery, ileocolonoscopy, and/or histopathology individually or as components of a global consensus. Small bowel was defined as any region distal to the pylorus up until the area proximal to the ileocecal junction. Authors of studies that combined small and large bowel data were contacted in order to obtain data for small bowel only. If we received no response, the study was excluded from the review. Studies which did not provide per-patient raw data (in terms of true positive, true negative, false positive, and false negative values) for the small bowel were also contacted for that information. If we received no response from the authors, they were still included in the review (including studies with only per-segment raw data) but excluded from the meta-analysis. Studies that comprised pediatric populations, were non-English, or used a reference standard that did not include surgery, ileocolonoscopy, or histopathology were excluded. Abstracts, conference presentations, and posters were also excluded.

All retrieved studies were sorted independently by two reviewers (Osman Ahmed and David Mario Rodrigues). Any disagreements were resolved either by consensus or by a third reviewer. Data from all selected studies was extracted independently by the same two reviewers (Osman Ahmed and David Mario Rodrigues). They followed a data extraction form that was created*a priori* and included study characteristics (year, country, age, gender, number of patients, type of study, reference standard, patient population, and location studied) and imaging characteristics (enterography versus enteroclysis, magnetic field strength, oral and intravenous contrast, bowel preparation, radiologist\'s experience, and time interval between MR and reference standard). Finally, specific values were extracted or calculated for studies that provided per-patient raw data (true positive, true negative, false positive, and false negative). For studies that included per-patient values for different segments of the small bowel, only the most distal part of the small bowel was included as this is the area most commonly affected by Crohn\'s disease.

Assessment of risk of bias, quality, and applicability was performed by using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-II) tool developed for diagnostic studies \[[@B11]\]. Studies with scores greater than 9 were categorized as low-risk.

2.3. Statistical Analysis {#sec2.3}
-------------------------

For studies that did not provide raw data, a summary of the results was presented for small bowel activity using sensitivity and specificity values. For studies providing raw data, 2 × 2 contingency tables were created using the following variables (true positive, true negative, false positive, and false negative). Statistical analysis was performed with use of Meta-DiSc version 1.4 (J. Zamora, A. Muriel, and V. Abraira Meta-DiSc for Windows, XI Cochrane Colloquium, Barcelona, 2003) software. Sensitivity, specificity, likelihood ratios, and 95% confidence intervals were calculated for each study. Figures for forest plots and summary receiver-operating characteristic (ROC) curves were also constructed using the software, while the area under the curve (AUC) was calculated. For pooled analysis, 0.5 was added to all cells that contained a value of 0 in order to include all studies in the analysis. Heterogeneity was assessed using the *I* ^2^ test.

3. Results {#sec3}
==========

The initial search yielded 3981 studies. These studies were initially sorted by title yielding 332 studies, which were then limited to 29 studies based on abstract review. After retrieving the full articles and contacting authors for missing information, only 27 studies met the inclusion criteria (Supplementary Figure 1). Of the 27 included studies, 19 provided sufficient raw data to be included in the pooled analysis; eight studies provided only summaries of the results \[[@B12]--[@B38]\]. All studies had a QUADAS-II score equal to or greater than 9, indicating low-risk.

3.1. Study Characteristics {#sec3.1}
--------------------------

Individual study characteristics are reported in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. A total of 19 studies with 1020 patients were included in the meta-analysis. Eight studies with a total of 650 patients were only included in the systematic review ([Table 3](#tab3){ref-type="table"}) \[[@B12]--[@B38]\].

There were 17 prospective studies \[[@B12], [@B15]--[@B17], [@B19], [@B21]--[@B23], [@B26]--[@B29], [@B31], [@B32], [@B34], [@B35], [@B38]\], 4 retrospective studies \[[@B25], [@B30], [@B33], [@B37]\], and one study \[[@B36]\] that had both retrospective and prospective components. An additional 5 studies were unclear in regard to the type of study \[[@B13], [@B14], [@B18], [@B20], [@B24]\]. In regard to patient population, 13 out of the 27 studies involved patients with established Crohn\'s disease \[[@B12], [@B14]--[@B17], [@B24], [@B26]--[@B30], [@B36]--[@B38]\]; 3 had only suspected CD \[[@B20], [@B21], [@B35]\]; and 11 had either suspected or established CD \[[@B13], [@B18], [@B19], [@B22], [@B23], [@B25], [@B28], [@B31]--[@B34]\]. Most prospective studies used consecutive patients to limit selection bias. Study characteristics for all studies are summarized in [Table 1](#tab1){ref-type="table"}.

In regard to imaging characteristics, most studies used a magnetic field strength of 1.5 T, with 2 studies using 1.0 T \[[@B12], [@B23]\] and 2 studies using 3.0 T \[[@B34], [@B35]\]. Three studies did not mention the magnetic field strength used \[[@B13], [@B31], [@B37]\]. Six of the 27 studies used enteroclysis as a method of introducing oral contrast \[[@B13], [@B14], [@B16], [@B18], [@B20], [@B31]\], while 19 studies used standard enterography. One study used both enterography and enteroclysis \[[@B19]\], while 1 study did not mention how oral contrast was given \[[@B15]\]; neither of these studies were included in the meta-analysis. Radiologist experience with abdominal MR and time interval between MR and the reference standard varied widely between the studies ([Table 2](#tab2){ref-type="table"}).

In regard to disease activity, unless otherwise specified below, we considered positive small bowel activity to be when the individual study considered the disease active (no specific parameters were used). Maccioni et al. \[[@B17]\] provided raw data for both T1-weighted and T2-weighted imaging. We chose to include T2-weighted results as they have been shown previously to be more accurate for small bowel activity \[[@B39]\]. Oto et al. selected for patients with active disease and thus had no results for specificity \[[@B30]\]. Because Seiderer et al. used an anterograde endoscopic approach, the jejunum was used for analysis as very few patients had their terminal ileum intubated \[[@B20]\]. For Adamek et al., we used histopathology as the reference standard rather than ileocolonoscopy (both were provided) \[[@B34]\]. Alternatively, for Siddiki et al., we used ileocolonoscopy as the reference standard since not as many patients had histopathology results \[[@B21]\]. For Kumar et al., we used bowel thickening as representative of small bowel activity \[[@B37]\]. Jensen et al. published two studies in 2011. Because there was no overlap in the study populations, both were included in our meta-analysis \[[@B28], [@B29]\].

### 3.1.1. Nonpooled Studies Summary {#sec3.1.1}

Of the 8 studies which were not included in the pooled analysis, by far the largest was Grand et al. with 310 patients (out of 650 total patients) \[[@B33]\]. Of these, 162 underwent MR and endoscopy within 30 days and the per-patient analysis for the distal ileum revealed a sensitivity of 85% and a specificity of 79% in diagnosing Crohn\'s disease activity. The results of the remaining studies are summarized in [Table 3](#tab3){ref-type="table"}.

3.2. Per-Patient Pooled Analysis {#sec3.2}
--------------------------------

Forest plots for the sensitivity, specificity, and sROC for the use of MR in diagnosing small bowel Crohn\'s disease activity are presented ([Figure 1](#fig1){ref-type="fig"}, Supplementary Figure 2). Pooled analysis of the 19 studies with raw data revealed a sensitivity of 0.88 (95% CI 0.86 to 0.91) with a heterogeneity of *χ* ^2^ = 80.38 and *I* ^2^ of 77.6% ([Figure 1](#fig1){ref-type="fig"}). The pooled specificity was 0.88 (95% CI 0.84 to 0.91) with a heterogeneity of *χ* ^2^ = 55.11 and *I* ^2^ of 67.3% ([Figure 1](#fig1){ref-type="fig"}). Using a random effects model, the positive likelihood ratio was 5.2 (95% CI 2.62 to 10.29) and the negative likelihood ratio was 0.17 (95% CI 0.11 to 0.27) (Supplementary Figure 3). Using Moses\' constant linear model, we were able to construct an sROC with an AUC of 0.93 (Supplementary Figure 2). As expected, most values reside in the left upper corner, suggesting high sensitivity and specificity.

3.3. Subgroup Analysis {#sec3.3}
----------------------

Analysis of only prospective studies revealed a pooled sensitivity of 0.89 (95% CI 0.86 to 0.92) and a pooled specificity of 0.90 (95% CI of 0.86 to 0.93) ([Figure 2](#fig2){ref-type="fig"}). Five studies used enteroclysis as the method of administrating oral contrast \[[@B14], [@B16], [@B18], [@B20], [@B31]\]. Pooled analysis of these 5 studies gave a sensitivity of 0.84 (95% CI of 0.74 to 0.91) and a pooled specificity of 0.89 (95% CI of 0.78 to 0.96) as demonstrated in the forest plots ([Figure 3](#fig3){ref-type="fig"}).

3.4. Extramural Complications {#sec3.4}
-----------------------------

We identified three extramural complications*a priori* (stenosis, fistula, and abscess). However, only two studies (Fallis et al. and Kumar et al.) \[[@B36], [@B37]\] provided raw data for analysis for fistulas and abscesses. Consequently, no pooled analysis was done for these complications. We conducted a pooled analysis and constructed forest plots for 6 studies that provided data for stenosis ([Figure 4](#fig4){ref-type="fig"}) \[[@B9], [@B27]--[@B29], [@B34], [@B36], [@B37]\]. Pooled sensitivity was 0.65 (95% CI 0.53 to 0.76) and pooled specificity was 0.93 (95% CI 0.89 to 0.96).

4. Discussion {#sec4}
=============

Our study represents the largest systematic review (in terms of patients and number of studies) of MR imaging for the detection of small bowel activity in Crohn\'s disease. Like previous studies and reviews, we demonstrate that MR imaging possesses high sensitivity and specificity in detecting small bowel activity \[[@B3], [@B9], [@B10]\]. Along with a relatively high positive likelihood ratio and relatively low negative likelihood ratio, it can be used in combination with pretest probabilities to determine small bowel activity in the appropriate clinical setting. The results from this meta-analysis are similar to those previously reported \[[@B9]\]. Of note, many of the studies differ from those included in previous reviews, not only because we focused only on the small bowel, but also because we included both studies with per-patient and per-segment analysis (though only per-patient analysis was pooled). Additionally, differences in response rates in regard to contacting authors likely explain the discrepancy in studies included in our review as compared to others.

One of the many research areas in MR imaging is the use of enteroclysis in inflammatory bowel disease. Enteroclysis has been proposed to provide better small bowel distension because the contrast is provided directly through nasojejunal intubation rather than orally \[[@B40]\]. The limitations of enteroclysis are that it is not as widely available, requires fluoroscopic insertion of a nasojejunal tube (thus exposing patients to radiation), and is less well tolerated by patients \[[@B41]\]. A subgroup analysis of studies using enteroclysis did not demonstrate higher sensitivity and specificity. Similarly, Negaard et al. directly compared use of oral contrast and enteroclysis and also did not find any significant difference \[[@B19]\]. One explanation for the lack of increment benefit of enteroclysis is because small bowel Crohn\'s disease usually affects the terminal ileum distally, rather than proximally, where the advantages of enteroclysis are more apparent. Overall, enteroclysis has not yet been shown to have any significant difference in diagnostic accuracy, and its role in Crohn\'s patients is still uncertain. Further study is warranted in determining potential benefits of enteroclysis in Crohn\'s disease proximal to the ileum.

In regard to intra- and extraluminal complications such as fistulas, abscesses, and stenosis, MR has been theorized to be the gold standard, since ileocolonoscopy can only assess luminal disease, and surgery is too invasive and not a feasible diagnostic modality. Our analysis revealed fairly high specificity in detecting stenosis, but only moderate sensitivity. However, our analysis was limited due to the small number of studies included. Previous studies looking at both small and large bowel have shown relatively high detection rates for stenosis \[[@B26], [@B42]\]. Nevertheless, a meta-analysis by Qiu et al. showed that CT imaging may be better at detecting fistulas and stenosis. However, the results were not statistically significant, and the sensitivities and specificities were comparable to more recently published studies \[[@B43], [@B44]\]. No differences were noted in detecting abscesses. The results for pooled analysis by Qiu et al. for stenosis revealed similar numbers to our study (sensitivity 65.3%, specificity 94.4%).

Current European guidelines recommend MR, US, and CT enterography or enteroclysis for the detection of intestinal involvement and penetrating lesions in CD. Additionally, the use of small bowel follow-through or small bowel enteroclysis is acceptable for detection of stenosis. They are also the recommended techniques for detection of extramural complications of CD \[[@B1], [@B45]\]. American guidelines are less specific but do include the use of MR, amongst a multitude of other imaging modalities, to delineate and discriminate intra-abdominal masses/abscesses and in the evaluation of small bowel pathology in patients with CD \[[@B46]\].

One of the difficulties in replacing the gold standard with MR imaging is the lack of standardization of the imaging signs suggestive of active disease, especially with the growing number of sequences available. Previous studies have demonstrated that the most accurate signs of inflammation for MR were wall enhancement, mucosal lesions, and wall T2 hyperintensity \[[@B39], [@B47]\]. In one study, Maccioni et al. looked at the difference using T1- versus T2-weighted imaging. They found that T2-weighted images provided greater sensitivity and specificity in diagnosing ileal lesions \[[@B17]\]. Additionally, a study by Udayasankar et al. found similar results in both the small and large bowel \[[@B48]\]. Previous studies have also found that sequences using diffusion-weighted imaging had high sensitivity and specificity \[[@B30], [@B49], [@B50]\]. Recently, there have been development of validated scoring systems including the MaRIA (Magnetic Resonance Index of Activity) score for assessment of disease activity and severity, the Lemann score, or the Crohn\'s Disease Digestive Damage Score, which takes into account many factors (clinical, endoscopic, and imaging findings) and attempts to measure cumulative damage \[[@B51], [@B52]\].

An important consideration is whether the results of MR imaging change clinician management. A study by Mendoza et al. showed that MR helped in decision-making in more than half of patients, especially those involving the use of biological therapies and surgery \[[@B53]\]. Messaris et al. showed that 69% of patients had changes to medical and/or surgical management after clinicians were given MR imaging results \[[@B54]\]. Similar results have shown that MR findings influence surgical approaches to managing Crohn\'s patients \[[@B55]\].

Some of the limitations of our study include the varied length of time between the reference standard and MR imaging. Since clinical activity can change quite drastically, especially with the use of medications, some of the results might have been inaccurate in determining disease activity. Secondly, since we used per-patient data, we were not able to differentiate severity in regard to determining small bowel activity. Other studies have suggested that MRI has good correlation with Crohn\'s severity indices \[[@B56]\]. Similarly, we were unable to perform per-segment analysis which might have led to an overestimation of the accuracy of MR imaging. This is likely due to the use of endoscopy as a reference standard and its inadequacy in assessing more proximal small bowel. Other limitations include the fact that we were only able to analyse one complication (stenosis), and that others (such as abscess and fistulas) are not well visualized on endoscopy. Similarly, due to the small number of studies, we were not able to determine whether more advanced MR (such as MR with 3.0 T magnetic field strength) had any additional benefit. Finally, the large heterogeneity amongst the studies, including reference standards, radiologists experience, and results, suggests that more definitive studies might still be required. Sources of heterogeneity include inclusion of studies of different sample size and different criteria for disease activity, as well as inclusion of studies using different MR enterography/enteroclysis protocols (including different magnetic field strengths, oral contrast, and radiologist experience).

In regard to other modalities of imaging, many studies assessed the use of ultrasound and computed tomography. The benefit of ultrasound is that it does not involve ionizing radiation and is relatively inexpensive \[[@B3]\]. Previous studies assessing ultrasound have demonstrated high sensitivities and specificities. There is one large-scale trial comparing US and MR currently in progress: the UK-based MR Enterography or Ultrasound in Crohn\'s disease (METRIC) trial \[[@B3], [@B57]\]. The use of US is thought to be limited by operator-experience; however MR has also been shown to have interobserver variability. However, the use of scoring systems such as MaRIA has been proven to improve interobserver agreement \[[@B58]\]. Similarly, one meta-analysis has shown similar accuracy between CT and MR. CT has the benefit of being widely available and cost-effective. It, however, also carries the risk of ionizing radiation, especially amongst patients who might require multiple scans throughout the course of their life-long disease \[[@B43]\].

In conclusion, MR imaging provides a reliable alternative to ileocolonoscopy in detecting small bowel activity in patients with Crohn\'s disease. Its advantages include high diagnostic accuracy, favorable safety profile, and the ability to assess intra- and extraluminal complications. Its disadvantages include high cost and limited availability. Nevertheless, with the rapid expansion in MR accessibility, it will likely play a greater role in the future in both the diagnosis and management of patients with Crohn\'s disease.
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###### 

Study characteristics.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                            Year   Country          Number of patients\   Age (range)     Prospective/retrospective   Patient population            Reference standard                                              Location studied                                      Pooled analysis\
                                                          (patients included)                                                                                                                                                                                                   (raw data available)
  ------------------------------- ------ ---------------- --------------------- --------------- --------------------------- ----------------------------- --------------------------------------------------------------- ----------------------------------------------------- ----------------------
  Rieber et al. \[[@B13]\]        2000   Germany          194 (84)              NS              NS                          Suspected or established CD   Ileocolonoscopy ± histopathology                                Small bowel                                           No

                                                                                                                                                                                                                                                                                

  Koh et al. \[[@B12]\]           2001   United Kingdom   30 (21)               37.6 (18--58)   Prospective                 Established CD                Surgery ± ileocolonoscopy                                       Small and large bowel                                 No

                                                                                                                                                                                                                                                                                

  Ochsenkühn et al. \[[@B14]\]    2004   Germany          29 (25)               31.5 (19--58)   NS                          Established CD                Ileocolonoscopy ± histology                                     Small bowel                                           Yes

                                                                                                                                                                                                                                                                                

  Pascu et al. \[[@B15]\]         2004   Germany          61 (37)               38 (19 to 84)   Prospective                 Established CD                Ileocolonoscopy                                                 Small and large bowel                                 No

                                                                                                                                                                                                                                                                                

  Schreyer et al. \[[@B16]\]      2005   Germany          30 (23)               29 (18--65)     Prospective                 Established CD                Ileocolonoscopy                                                 Small and large bowel (terminal ileum for analysis)   Yes

                                                                                                                                                                                                                                                                                

  Maccioni et al. \[[@B17]\]      2006   Italy            70 (59)               46.3 (18--76)   Prospective                 Established CD                Ileocolonoscopy ± imaging                                       Small and large bowel (ileum for analysis)            Yes

                                                                                                                                                                                                                                                                                

  Negaard et al. \[[@B18]\]       2006   Norway           60 (41)               33 (16--65)     NS                          Suspected or established CD   Ileocolonoscopy ± surgery                                       Small bowel (terminal ileum for analysis)             Yes

                                                                                                                                                                                                                                                                                

  Negaard et al. \[[@B19]\]       2007   Norway           48 (35)               39 (18--73)     Prospective                 Suspected or established CD   Surgery, ileocolonoscopy ± histopathology ± capsule endoscopy   Small bowel                                           No

                                                                                                                                                                                                                                                                                

  Seiderer et al. \[[@B20]\]      2007   Germany          10 (10)               33.9 (17--57)   NS                          Suspected CD                  Double-balloon enteroscopy (oral route)                         Small bowel (jejunum for analysis)                    Yes

                                                                                                                                                                                                                                                                                

  Siddiki et al. \[[@B21]\]       2009   USA              33 (27)               39 (20--60)     Prospective                 Suspected CD                  Ileocolonoscopy ± histopathology                                Small bowel                                           Yes

                                                                                                                                                                                                                                                                                

  Lee et al. \[[@B22]\]           2009   South Korea      31 (23)               28.8 (18--44)   Prospective                 Suspected or established CD   Ileocolonoscopy                                                 Small bowel                                           Yes

                                                                                                                                                                                                                                                                                

  Giusti et al. \[[@B24]\]        2010   Italy            70 (70)               27.8 (15--45)   NS                          Established CD                Histopathology                                                  Small bowel                                           Yes

                                                                                                                                                                                                                                                                                

  Parisinos et al. \[[@B25]\]     2010   United Kingdom   342 (68)              36.8 (25--47)   Retrospective               Suspected or established CD   Surgery, ileocolonoscopy ± histopathology                       Small bowel                                           No

                                                                                                                                                                                                                                                                                

  Fiorino et al. \[[@B26]\]       2011   Italy            44 (44)               43 (19--61)     Prospective                 Established CD                Ileocolonoscopy                                                 Small and large bowel (ileum for analysis)            No

                                                                                                                                                                                                                                                                                

  Gallego et al. \[[@B23]\]       2011   Spain            61 (61)               36.1 (14--65)   Prospective                 Suspected or established CD   Ileocolonoscopy                                                 Small bowel (ileum for analysis)                      Yes

                                                                                                                                                                                                                                                                                

  Hyun et al. \[[@B27]\]          2011   Japan            30 (25)               29.5 (24--38)   Prospective                 Established CD                Ileocolonoscopy ± double-balloon enteroscopy (rectal route)     Small and large bowel (small bowel for analysis)      Yes

                                                                                                                                                                                                                                                                                

  Jensen et al. \[[@B28]\]        2011   Denmark          93 (72)               30 (15--74)     Prospective                 Suspected or established CD   Ileocolonoscopy ± surgery                                       Small bowel                                           Yes

                                                                                                                                                                                                                                                                                

  Jensen et al. \[[@B29]\]        2011   Denmark          53 (45)               39 (18--76)     Prospective                 Established CD                Ileocolonoscopy ± surgery                                       Small bowel                                           Yes

                                                                                                                                                                                                                                                                                

  Oto et al. \[[@B30]\]           2011   USA              18 (18)               33.2 (20--53)   Retrospective               Established CD                Endoscopy ± histopathology                                      Small bowel                                           Yes

                                                                                                                                                                                                                                                                                

  Wiarda et al. \[[@B31]\]        2012   Netherlands      41 (38)               36 (20--74)     Prospective                 Suspected or established CD   Balloon-assisted enteroscopy and consensus                      Small bowel                                           Yes

                                                                                                                                                                                                                                                                                

  Friedrich et al. \[[@B32]\]     2012   Germany          79 (39)               27.8 (23--48)   Prospective                 Suspected or established CD   Ileocolonoscopy                                                 Small and large bowel (ileum for analysis)            No

                                                                                                                                                                                                                                                                                

  Grand et al. \[[@B33]\]         2012   USA              310 (310)             45 (20--94)     Retrospective               Suspected or established CD   Ileocolonoscopy ± histopathology                                Small and large bowel                                 No

                                                                                                                                                                                                                                                                                

  Adamek et al. \[[@B34]\]        2012   Germany          104 (82)              39.8 (18--68)   Prospective                 Suspected or established CD   Ileocolonoscopy + histopathology                                Small bowel (terminal ileum for analysis)             Yes

                                                                                                                                                                                                                                                                                

  Castiglione et al. \[[@B35]\]   2013   Italy            265 (234)             39              Prospective                 Suspected CD                  Ileocolonoscopy ± surgery                                       Small bowel                                           Yes

                                                                                                                                                                                                                                                                                

  Fallis et al. \[[@B36]\]        2013   United Kingdom   51 (51)               41.3 (17--79)   Both                        Established CD                Surgery                                                         Small and large bowel (distal ileum for analysis)     Yes^1^

                                                                                                                                                                                                                                                                                

  Takenaka et al. \[[@B38]\]      2014   Japan            100 (100)             31 (16--71)     Prospective                 Established CD                Balloon-assisted enteroscopy (rectal route)                     Small bowel (terminal ileum for analysis)             Yes

                                                                                                                                                                                                                                                                                

  Kumar et al. \[[@B37]\]         2015   United Kingdom   17 (17)               30.8 (19--72)   Retrospective               Established CD                Surgery                                                         Small bowel                                           Yes
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Provided by author.

###### 

Imaging characteristics.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                            Year   Enterography/\   Magnetic field strength   Type of coil                                               Bowel preparation                        Intravenous contrast                     Oral contrast                                                                                Blinded   Radiologist experience                          Time interval between MR and RS
                                         enteroclysis                                                                                                                                                                                                                                                                                                                                   
  ------------------------------- ------ ---------------- ------------------------- ---------------------------------------------------------- ---------------------------------------- ---------------------------------------- -------------------------------------------------------------------------------------------- --------- ----------------------------------------------- --------------------------------------
  Rieber et al. \[[@B13]\]        2000   Enteroclysis     NS                        NS                                                         20 mg IV N-butyl scopolamine             Gadolinium-DTPA                          800 mL barium sulfate solution and 1200 mL methyl cellulose solution                         NS        NS                                              NS

                                                                                                                                                                                                                                                                                                                                                                                        

  Koh et al. \[[@B12]\]           2001   Enterography     1.0 T                     NS                                                         1 mg IM glucagon                         0.1 mmol/kg gadodiamide                  600 mL water                                                                                 Yes       NS                                              Median 21 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Ochsenkühn et al. \[[@B14]\]    2004   Enteroclysis     1.5 T                     NS                                                         30--60 mg IV butylscopolamine            0.1 mmol/kg gadolinium-DTPA              1500--2000 mL of a suspension (12 g iron-containing Ferristen) + 20 g methylcellulose (NJ)   Yes       Two experienced gastrointestinal radiologists   Median of 10 (3--13) weeks

                                                                                                                                                                                                                                                                                                                                                                                        

  Pascu et al. \[[@B15]\]         2004   NS               1.5 T                     Body coils                                                 NS                                       0.2 mmol/kg gadolinium-DTPA              NS                                                                                           Yes       NS                                              Within 5 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Schreyer et al. \[[@B16]\]      2005   Enteroclysis     1.5 T                     Polarized 4-element phased-array body coil                 40 mg IV N-butyl-scopolamine             0.2 mmol/kg gadolinium-DTPA              1000 mL water (25 g mannitol and 5 g carob seed)                                             Yes       NS                                              Within 1 week

                                                                                                                                                                                                                                                                                                                                                                                        

  Maccioni et al. \[[@B17]\]      2006   Enterography     1.5 T                     Phased-array coil                                          NS                                       0.18 mmol/kg gadopentetate dimeglumine   600--900 mL ferumoxsil solution                                                              Yes       \>8 years of experience and resident            Within 15 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Negaard et al. \[[@B18]\]       2006   Enteroclysis     1.5 T                     Phased-array abdomen surface coil                          20 mg IV scopolamine butylbromide        0.1 mmol/kg gadolinium-DTPA              1500--2000 mL polyethylene glycol                                                            Yes       Two and 1 years of experience with MRE          Within 4 months

                                                                                                                                                                                                                                                                                                                                                                                        

  Negaard et al. \[[@B19]\]       2007   Both             1.5 T                     Phased-array coils                                         20 mg IV scopolamine butylbromide        0.1 mmol/kg gadolinium-DTPA              1000 mL of 6% mannitol or 1500--2000 mL of polyethylene glycol solution (NJ)                 Yes       \>8- and \>3-year experience                    Within 3 months

                                                                                                                                                                                                                                                                                                                                                                                        

  Seiderer et al. \[[@B20]\]      2007   Enteroclysis     1.5 T                     NS                                                         40 mg IV butylscopolammonium bromide     0.1 mmol/kg gadolinium-DTPA              2500 mL 0.5% methylcellulose solution (NJ)                                                   NS        Two board-certified radiologists                Within 6 weeks after MRE

                                                                                                                                                                                                                                                                                                                                                                                        

  Siddiki et al. \[[@B21]\]       2009   Enterography     1.5 T                     16-channel torso array coil                                0.5 mg IV glucagon                       0.2 mmol/kg gadodiamide                  1350 mL barium preparation                                                                   Yes       NS                                              Within 30 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Lee et al. \[[@B22]\]           2009   Enterography     1.5 T                     Two six-element, phased-array body coils                   20 mg IV scopolamine-*N*-butyl bromide   15 mL of gadopentetate dimeglumine       1200 mL 3% sorbitol solution and 4000 mL polyethylene glycol solution                        Yes       Six- and 10-year experience                     Within 1 week

                                                                                                                                                                                                                                                                                                                                                                                        

  Giusti et al. \[[@B24]\]        2010   Enterography     1.5 T                     Two phased-array coils                                     20 mg IV hyoscine-*N*-butylbromide       0.1 mL/kg 1.0 M gadolinium chelate       1500--2000 mL polyethylene glycol solution                                                   Yes       Two with \>10-year experience                   NS

                                                                                                                                                                                                                                                                                                                                                                                        

  Parisinos et al. \[[@B25]\]     2010   Enterography     1.5 T                     Two multichannel phased-array body coils                   20 mg IV hyoscine-*N*-butylbromide       15 mL of gadolinium chelate              1500 mL of 2.5% mannitol and 0.5% locust bean gum solution                                   NS        NS                                              Within 8.5 to 112 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Fiorino et al. \[[@B26]\]       2011   Enterography     1.5 T                     Phased-array surface coil                                  0.5 mg of glucagon IV                    Gadolinium                               700 mL polyethylene glycol solution                                                          Yes       Two with \>8-year experience                    Within 26 days (range 0--37)

                                                                                                                                                                                                                                                                                                                                                                                        

  Gallego et al. \[[@B23]\]       2011   Enterography     1.0 T                     Multichannel-body coil                                     20--40 mg IV hyoscine bromide            0.1 mmol/kg gadopentetate dimeglumine    1500 mL polyethylene glycol solution                                                         Yes       Two experienced radiologists                    Within 15 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Hyun et al. \[[@B27]\]          2011   Enterography     1.5 T                     32-element body coil                                       20 mg IV scopolamine butylbromide        0.2 mL/kg gadolinium chelate             1000 mL--1500 mL polyethylene glycol solution                                                Yes       Two board-certified radiologists                Same day

                                                                                                                                                                                                                                                                                                                                                                                        

  Jensen et al. \[[@B28]\]        2011   Enterography     1.5 T                     Five-element Syn-body coil                                 20 mg IV Hyoscinbutylbromide             0.1 mmol/kg gadodiamide                  1000 mL 7.5% mannitol solution                                                               Yes       Five with \>4-year experience                   Median 13 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Jensen et al. \[[@B29]\]        2011   Enterography     1.5 T                     Five-element Syn-body coil                                 20 mg IV Hyoscinbutylbromide             0.1 mmol/kg gadodiamide                  1000 mL 7.5% mannitol solution                                                               Yes       Five with \>4-year experience                   Median 11 days (51 days for surgery)

                                                                                                                                                                                                                                                                                                                                                                                        

  Oto et al. \[[@B30]\]           2011   Enterography     1.5 T                     Four-channel phased-array body coil                        1 mg IM glucagon                         0.1 mmol/kg gadodiamide                  1350 mL Volumen                                                                              NS        12 years of experience in body MRI              Median of 14 (0--62) days

                                                                                                                                                                                                                                                                                                                                                                                        

  Wiarda et al. \[[@B31]\]        2012   Enteroclysis     NS                        NS                                                         20 mg IV butylscopolamine bromide        0.1 mmol/kg of gadobutrol                1000--3000 mL 0.5% methylcellulose solution (ND)                                             Yes       \>200 MRE studies                               Median of 22 (4--112) days

                                                                                                                                                                                                                                                                                                                                                                                        

  Friedrich et al. \[[@B32]\]     2012   Enterography     1.5 T                     Circular polarized 6-channel phased-array body coil        40 mg IV N-butyl scopolamine             0.1 mmol/kg gadolinium-DTPA              1000 mL water (25 g mannitol and 5 g carob seed) and 2000 mL water                           Yes       Two with 6- and 7-year experience               Within 3 weeks

                                                                                                                                                                                                                                                                                                                                                                                        

  Grand et al. \[[@B33]\]         2012   Enterography     1.5 T                     Eight-channel torso array coil or 4-channel surface coil   NS                                       0.1 mmol/kg gadopentetate dimeglumine    900 mL Volumen                                                                               Yes       \>4-year experience                             Within 90 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Adamek et al. \[[@B34]\]        2012   Enterography     3.0 T                     Two surface coils                                          40 mg IV hyoscine-*N*-butylbromide       Gadodiamide                              1500 to 2000 mL mannitol solution                                                            Yes       \>5-year experience                             Within 7 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Castiglione et al. \[[@B35]\]   2013   Enterography     3.0 T                     Two-paired phased-array body coils                         20 mg IV N-butylscopolamine              0.2 mmol/kg gadopentetate dimeglumine    1500 mL polyethylene glycol solution                                                         Yes       Two expert radiologists                         NS

                                                                                                                                                                                                                                                                                                                                                                                        

  Fallis et al. \[[@B36]\]        2013   Enterography     1.5 T                     Abdominal phased-array coils                               20 mg IV hyoscine-*N*-butylbromide       0.2 mL/kg gadoterate meglumine           1200--1300 mL 3% mannitol solution                                                           Yes       Dedicated gastrointestinal radiologist          Mean 10.8 (1--52) weeks

                                                                                                                                                                                                                                                                                                                                                                                        

  Takenaka et al. \[[@B38]\]      2014   Enterography     1.5 T                     NS                                                         20 mg IV scopolamine butylbromide        0.2 mL/kg gadolinium chelate             1000 mL polyethylene glycol                                                                  Yes       Two board-certified radiologists                Within 3 days

                                                                                                                                                                                                                                                                                                                                                                                        

  Kumar et al. \[[@B37]\]         2015   Enterography     NS                        Eight-channel body coil                                    Hyoscine butylbromide                    0.2 mL/kg gadolinium                     250 mL 20% mannitol solution                                                                 NS        NS                                              Mean 77.4 days
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NS: not specified; NJ: nasojejunal intubation; ND: nasoduodenal intubation.

###### 

Results (of nonpooled studies).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                          Year   Number of patients\                         Results
                                       (number of patients included in analysis)   
  ----------------------------- ------ ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------
  Rieber et al. \[[@B13]\]      2000   194 (84)                                    Sensitivity and specificity of 95.2% and 92.6% in terminal ileum

                                                                                   

  Koh et al. \[[@B12]\]         2001   30 (21)                                     Sensitivity and specificity of 89% and 67% in terminal ileum

                                                                                   

  Pascu et al. \[[@B15]\]       2004   61 (37)                                     Per-segment sensitivity and specificity of 56% and 73% in terminal ileum

                                                                                   

  Negaard et al. \[[@B19]\]     2007   48 (35)                                     Sensitivity and specificity of 88% and 89% for MRI with OS, and 88% and 84% for MR enteroclysis

                                                                                   

  Parisinos et al. \[[@B25]\]   2010   342 (68)                                    Sensitivity and specificity of 85.1% and 85.71% in ileum

                                                                                   

  Fiorino et al. \[[@B26]\]     2011   44 (44)                                     Sensitivity and specificity of 93% and 81% in ileum

                                                                                   

  Friedrich et al. \[[@B32]\]   2012   79 (39)                                     Sensitivity and specificity of 72% and 87% in terminal ileum without rectal enema; 100% and 74% in terminal ileum with rectal enema

                                                                                   

  Grand et al. \[[@B33]\]       2012   310 (310)                                   Sensitivity and specificity of 85% and 79% in distal ileum
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
